Abbott Molecular, Inc. appears in FDA device records as the applicant for Alinity m HR HPV under PMA number P230003, product code MAQ, with a filing address at 1300 East Touhy Avenue, Des Plaines, Illinois. The public information covers the original approval and a later supplement, and it identifies the product as a laboratory test rather than a therapeutic. The same applicant name appears on both records, and Abbott Molecular Inc. is described in device labeling as the legal manufacturer of the Alinity m HR HPV AMP Kit. [1][2][9]
The approved test and what it detects
The original approval describes Alinity m HR HPV as a qualitative in vitro test for Human Papillomavirus DNA in cervical specimens collected by a health care professional using an endocervical brush or spatula placed in ThinPrep PreservCyt Solution, or an endocervical broom placed in SurePath Preservative Fluid. The test identifies high-risk HPV types 16, 18 and 45 while reporting concurrent detection of the genotype groups 31/33/52/58 and 35/39/51/56/59/66/68. Its stated indication covers routine cervical cancer screening, triage of ASC-US cytology, co-testing with cytology and HPV primary screening, with follow-up per professional guidelines and patient history. [2]
Abbott's product page states that the assay detects 14 high-risk HPV genotypes in one reaction and separately reports 16, 18 and 45. The labeling identifies the Alinity m HR HPV AMP Kit under List No. 09N15-095 and the Alinity m HR HPV CTRL Kit under List No. 09N15-085, and names Abbott Molecular Inc. as legal manufacturer of the AMP Kit. [6][9][10]
Filing history in the linked FDA records
PMA P230003 was received on 31 January 2023 and approved on 1 November 2023, with a Federal Register notice date of 16 November 2023 and docket number 23M-4997. The advisory committee is listed as Microbiology, and the expedited review flag is recorded as N. [2]
Supplement P230003/S019 was received on 28 August 2026 and decided on 2 September 2026 under decision code OK30, a 30-Day Notice. Its supplement reason is recorded as a process change involving manufacturer, sterilizer, packager or supplier, and its additional information statement reads "replacement of an instrument part." The supplement carries the same product code and advisory committee as the original approval. [1]
A separate summary document for P230003/S006 records FDA notice of approval on 10 September 2025 and states that the original PMA was approved earlier; the supplied excerpt does not give that earlier date. The supplied collection lists two linked PMA records, one with decision APPR and one with OK30, and the smaller record sample shows the same one-to-one split. These counts describe the supplied filings only, not total company portfolio or sales. [1][2][5]
Applicant identity and scope limits
The applicant name on both PMA records is Abbott Molecular, Inc., and the filing address is in Des Plaines, Illinois. That address is a filing address in the FDA record and is not presented here as a corporate headquarters. The public documents do not establish parent ownership, corporate structure or a verified brand relationship beyond the applicant name and the manufacturer statement in the labeling. [1][2][9]
Abbott's website text carries a country-specific notice stating that the site is intended for residents of particular countries and may contain product information not approved elsewhere. The same page labels the assay for in vitro diagnostic use, Rx only. No customer list, certification, independent performance result or commercial availability claim is documented in the public information. [6][10]


